Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124530132 | 12453013 | 2 | F | 201506 | 20160622 | 20160609 | 20160701 | EXP | GB-TEVA-665854ACC | TEVA | 0.00 | A | F | Y | 0.00000 | 20160701 | MD | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124530132 | 12453013 | 1 | PS | AZITHROMYCIN ANHYDROUS. | AZITHROMYCIN ANHYDROUS | 1 | Oral | 500 MG, QW3 | Y | U | 65150 | FILM-COATED TABLET | TIW | ||||||
| 124530132 | 12453013 | 2 | SS | AZITHROMYCIN ANHYDROUS. | AZITHROMYCIN ANHYDROUS | 1 | Oral | 1500 MILLIGRAM DAILY; 1500 MG, QD | Y | U | 65150 | 1500 | MG | FILM-COATED TABLET | QD | ||||
| 124530132 | 12453013 | 3 | C | CO-AMOXICLAV | AMOXICILLINCLAVULANIC ACID | 1 | 1875 MILLIGRAM DAILY; 625 MG, TID | 0 | 625 | MG | TID | ||||||||
| 124530132 | 12453013 | 4 | C | ETANERCEPT | ETANERCEPT | 1 | Subcutaneous | 50 MG, QW | 0 | 50 | MG | /wk | |||||||
| 124530132 | 12453013 | 5 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 15 MILLIGRAM DAILY; 15 MG, QD | 0 | 15 | MG | QD | |||||||
| 124530132 | 12453013 | 6 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 1 GRAM DAILY; 1 G, QD | 0 | 1 | G | QD | |||||||
| 124530132 | 12453013 | 7 | C | METHOTREXATE. | METHOTREXATE | 1 | Oral | 10 MG, QW | 0 | 10 | MG | /wk | |||||||
| 124530132 | 12453013 | 8 | C | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 5 MG, UNK | 0 | 5 | MG | ||||||||
| 124530132 | 12453013 | 9 | C | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | 20 MILLIGRAM DAILY; 20 MG, QD | 0 | 20 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124530132 | 12453013 | 1 | Lower respiratory tract infection |
| 124530132 | 12453013 | 3 | Sinusitis |
| 124530132 | 12453013 | 4 | Psoriatic arthropathy |
| 124530132 | 12453013 | 5 | Product used for unknown indication |
| 124530132 | 12453013 | 6 | Type 2 diabetes mellitus |
| 124530132 | 12453013 | 7 | Psoriatic arthropathy |
| 124530132 | 12453013 | 8 | Arthritis |
| 124530132 | 12453013 | 9 | Hypercholesterolaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124530132 | 12453013 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124530132 | 12453013 | Diarrhoea | |
| 124530132 | 12453013 | Disturbance in attention | |
| 124530132 | 12453013 | Headache | |
| 124530132 | 12453013 | Hypoacusis | |
| 124530132 | 12453013 | Overdose |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124530132 | 12453013 | 1 | 20150526 | 20150611 | 0 | |
| 124530132 | 12453013 | 2 | 20150612 | 20150722 | 0 | |
| 124530132 | 12453013 | 3 | 20150526 | 20150602 | 0 |